TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01575054

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: botulinum toxin Type A
Description: Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline
Description: Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
Study: NCT03491358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wright jet nebulizer
Description: Roxon Medi-Tech, Montreal, QC, Canada

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerogen Solo
Description: Aerogen Ltd., Galway, Ireland
Study: NCT03123003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonicBone Ultrasound
Description: Bone age assessment by SonicBone Ultrasound. The patient needs to put his/her wrist in 3 positions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist X-ray
Description: Bone age assessment by Wrist X-ray
Study: NCT00459368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback of patient adherence information
Description: Patient inhaled corticosteroid adherence information is being provided to physicians at clinic sites randomized to the intervention arm. Adherence information is available via electronic prescribing software, and so is available to physicians when writing, renewing, or viewing medications. Physicians at intervention sites also receive standard training in how to interpret adherence metrics and how to intervene on poor adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
Study: NCT00290693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m2, IV, days 1 and 8 every 3 weeks
Study: NCT03647423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin Hydrochloride
Description: Aldoxorubicin Hydrochloride HCI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: haNK™, NK-92 \[CD16.158V, ER IL-2\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Capsules

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic body radiation therapy
Study: NCT03797131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KB195 (a novel mixture of oligosaccharides)
Description: KB195 (a novel mixture of oligosaccharides) for oral intake for 21 days.
Study: NCT03173495

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FRUCTOSE
Description: Fructose-rich beverage with a high fat meal, without exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FRUCTOSE
Description: Fructose-rich beverage with a high fat meal, without exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: DEXTROSE
Description: Dextrose-rich beverage with a high fat meal (control), without exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EXERCISE
Description: 45 minutes of 60% VO2peak aerobic exercise
Study: NCT00538512

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: single dose licensed trivalent inactivated influenza vaccine (2007-08)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flumist
Description: single dose licensed live-attenuated influenza vaccine Flumist (2007-08)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: single dose placebo administered as an intranasal spray or intramuscular injection
Study: NCT02349282

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcifediol 10ug/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 20ug/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03326518

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumentin® 44
Description: Contrast agent

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diluted Omnipaque®
Description: Contrast agent

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Movprep®
Description: Contrast agent
Study: NCT03259906

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH score
Description: Questionnaire asking about Disability of Arm, Shoulder and Hand

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH score
Description: Questionnaire asking about Disability of Arm, Shoulder and Hand

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: postoperative x-rays at 6 weeks, 3, 6 and 12 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: postoperative x-rays at 6 weeks, 3, 6 and 12 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior osteosynthesis
Description: Osteosynthesis using a posterior plate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior osteosynthesis
Description: Osteosynthesis using an anterior plate
Study: NCT02653898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-PIP
Description: Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-PIP
Description: Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-PIP
Description: Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-PIP
Description: Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
Study: NCT01076764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otamixaban
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otamixaban
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Otamixaban)
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFH
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for UFH)
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for UFH)
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptifibatide
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Eptifibatide)
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Eptifibatide)
Description: Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion
Study: NCT01639742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New texture round breast implants
Description: Breast implant surgery
Study: NCT00321685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT02653898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
Study: NCT00321685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT02820545

Intervention type: OTHER
Intervention: Sociological interview
Description: A sociological interview will be performed with each patient by a sociologist, during their hospital stay

Intervention type: OTHER
Intervention: Self-administrated questionnaire
Description: Self-administrated questionnaire will be performed by patients themselves at the end of hospital stay and one week after they left hospital
Study: NCT02952859

Intervention type: OTHER
Intervention: Irreversible electroporation
Study: NCT01775293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-absorbable polypropylene mesh
Description: 2 step procedures~* first step is insertion of Non-absorbable polypropylene mesh under the facial skin~* second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step
Study: NCT01550523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-1R/AS ODN
Description: Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biodiffusion chamber
Description: The biodiffusion chamber is a simple construct comprised of two Lucite rings sealed on either side with a 0.1u mesh filter (Durapore, the Millipore Corporation). Autologous tumor cells pretreated with the IGF-1R AS ODN and resuspended with 2ug of exogenous IGF-1R AS ODN are added to the chamber. Implantation of the chambers (maximum 10 chambers) occurs 24 hours post surgery for 24 hours.
Study: NCT03082755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil
Description: 1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
Study: NCT00002463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOPP Regimen
Description: Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechlorethamine Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Study: NCT02653898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate + Mefloquine
Description: Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate + Mefloquine
Description: Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin (Insecticide treated uniform)
Description: 40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin (Insecticide treated uniform)
Description: 40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
Study: NCT01375374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
Study: NCT00368641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extraneal
Description: Periotneal Dialysis
Study: NCT01674322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
Study: NCT01375374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
Study: NCT01810744

Intervention type: OTHER
Group type: OTHER
Intervention: capillaroscopy

Intervention type: OTHER
Group type: OTHER
Intervention: capillaroscopy

Intervention type: OTHER
Group type: OTHER
Intervention: blood pressure measurement

Intervention type: OTHER
Group type: OTHER
Intervention: blood pressure measurement
Study: NCT03952026

Intervention type: PROCEDURE
Intervention: osteosynthesis of the pelvis
Description: Osteosynthetic Fixation of the pelvic fracture

Intervention type: PROCEDURE
Intervention: osteosynthesis of the pelvis
Description: Osteosynthetic Fixation of the pelvic fracture
Study: NCT02550925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) Group
Description: A 7-session Acceptance and Commitment Therapy (ACT) group intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Check in with clinical social worker at oncology care site and obtain list of supportive resources
Study: NCT05440721

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment A with device Clickotine® (Active intervention)
Description: The intervention regimen around Treatment A is almost entirely user-directed. When a person has a craving, a series of options are available to ease the craving and resist the urge to smoke. The user will also engage with Clickotine® leading up to their quit date to complete a program of 21 Missions, daily activities which help prepare them to quit and keep them off cigarettes. Ideally, the user will open and use Treatment A several times a day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Treatment B with smoking education (control)
Description: The Treatment B app is operated by the National Cancer Institute to provide education and support to smokers seeking to quit. The QG regimen is entirely user-directed. When a user has a craving or wants support or education, they can log into the QG app. The QG app also provides lessons relevant for preparing to quit and beginning to quit.
Study: NCT00828269

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Comparator: Fine needle aspiration biopsy
Description: Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.~Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit
Study: NCT01955577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo orally everyday
Study: NCT00997711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cypher
Description: Sirolimus-eluting stents
Study: NCT04486976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cornea/Anterior Segment OCT CASIA2
Description: Cornea/Anterior Segment OCT CASIA2 The Tomey Cornea/Anterior Segment OCT CASIA2 is a non-contact, high resolution tomographic and biomicroscopic device indicated for the in vivo imaging and measurement of ocular structures in the anterior segment, such as corneal thickness. The Tomey Cornea/Anterior Segment OCT CASIA2 is indicated as an aid in the visualization of anterior segment findings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cornea/Anterior Segment OCT CASIA2
Description: Cornea/Anterior Segment OCT CASIA2 The Tomey Cornea/Anterior Segment OCT CASIA2 is a non-contact, high resolution tomographic and biomicroscopic device indicated for the in vivo imaging and measurement of ocular structures in the anterior segment, such as corneal thickness. The Tomey Cornea/Anterior Segment OCT CASIA2 is indicated as an aid in the visualization of anterior segment findings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cornea/Anterior Segment OCT CASIA2
Description: Cornea/Anterior Segment OCT CASIA2 The Tomey Cornea/Anterior Segment OCT CASIA2 is a non-contact, high resolution tomographic and biomicroscopic device indicated for the in vivo imaging and measurement of ocular structures in the anterior segment, such as corneal thickness. The Tomey Cornea/Anterior Segment OCT CASIA2 is indicated as an aid in the visualization of anterior segment findings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optovue RTVue XR Avanti
Description: Optovue RTVue XR Avanti The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optovue RTVue XR Avanti
Description: Optovue RTVue XR Avanti The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optovue RTVue XR Avanti
Description: Optovue RTVue XR Avanti The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
Study: NCT01256671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
Study: NCT02419768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
Study: NCT00846508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is available commercially as a sterile lyophilized white power in single-dose amber vials containing 10 mg or 50 mg of cisplatin for administration by IV infusion. Every effort should be made to obtain and record the lot numbers of the batches of cisplatin used. Unopened vials of cisplatin are stable for the shelf-life indicated on the package when stored in accordance with the manufacturers' instructions.